Canaccord analyst Dewey Steadman noted Endo shares have been under pressure due to concerns over the sustainability of the company’s ex-injectables generics business and from competitors’ news on the opioid litigation front. The analyst is looking for several upcoming catalysts for the company this year and continued execution on the company’s key franchises, which he believes will lead to a second half of the year impact. Steadman reiterated his Buy rating and lowered his price target to $17 from $20 on Endo shares.
https://thefly.com/landingPageNews.php?id=2876449
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.